<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did X4 Pharmaceuticals' revenue and expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 00:22am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">X4 Pharmaceuticals experienced a significant decline in net income in Q4 2024, with a net loss of $39.82 million, compared to the previous quarter's net income of $1.43 million. The company's revenue for the quarter was $1.43 million, while the R&amp;D expenses were $21.7 million. 


|code|Ticker|Name|Date|R&amp;D Expenses|Total Revenue|Net Income|market_code|
|---|---|---|---|---|---|---|---|
|XFOR|XFOR.O|X4 Pharmaceuticals|2023 Q4|1.5272E7||-1.913E7|186|
|XFOR|XFOR.O|X4 Pharmaceuticals|2024 Q1|1.9854E7||-5.1766E7|186|
|XFOR|XFOR.O|X4 Pharmaceuticals|2024 Q2|2.0914E7|563000|9.0833E7|186|
|XFOR|XFOR.O|X4 Pharmaceuticals|2024 Q3|1.9173E7|560000|-3.6696E7|186|

</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax){return {layout:"default",data:[{noData:c,currentQuestion:g,textDescription:X,comeFrom:"AInvestShareLink",events:[],answerSource:p}],fetch:{},error:q,state:{sharePreviewModule:{loadJgySuccess:e,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:h,agent_id:a,output_media_info:[],task_id:a,language:a,source:p,cache_builder:a,reply_action:"Answer",execute_mode:I,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did X4 Pharmaceuticals' revenue and expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did X4 Pharmaceuticals' revenue and expenses trend in Q4 2024?\",\"user_id\":\"dp54012389\",\"user_name\":\"\",\"trace_id\":\"886cdcca-1e3c-4f79-8908-cc9792d8283a\",\"session_id\":\"886cdcca-1e3c-4f79-8908-cc9792d8283a\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:j,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Total Revenue[20241231]|R&D Expenses[20241231]|Total Expenses[20241231]|Net Income[20241231]|Report End Date|\n|---|---|---|---|---|---|---|---|---|\n|XFOR|X4 Pharmaceuticals|$3.27|0.93%|$1.43 million|$21.7 million||-$39.82 million|20241231|\n",query_data:{number:h,title:J,query_type:j,condition:a,model_sql:Y,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:e}}}],answer_chain_name:Z,agent_mode:_,native_answer:a,come_from:a,text_answer:X,trace_id:i,cost:20092,event_names:a,question:g,fallback_type:$,input_type:aa,fall_back_reason:{fall_back_type:$,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:i,first_return_cost:3709,cache_type:"no_cache",question_id:i,transfer_question:g,signal_type:"ON_COMPLETE",start_time:K,remote_svc:p,slots:[],answer_type:I,user_id:A,skill_name:L},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:i,session_id:i,user_id:A,question:g,source:p,raw_question:g,version:"3.4.1",action_name:L,nlu:{entity:[{type:ab,value:r,market:k}]},output_time:K,deep_research:c,deep_thinking:c,agent_mode:_},extra:{}},{answer_path:B,section:{id:C,info_texts:["Thinking"],show_type:D,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:B,section:{id:C,info_texts:["Querying Stock: XFOR Revenue (Q4 2024), R&D Expenses (Q4 2024), SG&A Expenses (Q4 2024), Net Income (Q4 2024)"],show_type:D,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:J,thought:"The user seeks to analyze X4 Pharmaceuticals' (XFOR) revenue and expense trends in Q4 2024. I should focus on XFOR's Q4 2024 revenue, R&D expenses, SG&A expenses, and net income data. I will use FinQuery for the data mentioned above."}},{answer_path:d,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:B,section:{id:C,info_texts:["Generating Answer"],show_type:D,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:t,voice_txt:"X",text_answer:ac,rich_text:ac,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:t,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:J,query_type:j,trace_data:a,index:h,model_sql:Y,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:e},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:t,voice_txt:M,text_answer:M,rich_text:M,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:u,market_id:k,name:n,domain:ab},pos:e,section_id:m,txt:n,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:t,voice_txt:"\n",text_answer:ad,rich_text:ad,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:ae,choice:[],result_page:{components:[{uuid:"ef6a0c13d86a2302",config:{score:116,show_type:af,scoreRuleNames:"value_unit;data_size;",showDataZoom:b,show_type_id:131,title:"分组柱状图",render:{x:v,y:[E,F,G]},title_config:{config:{display:b,display2:c,txt_style:e,url:a},data:{h1:ag,h2:a},show_type:N}},data:{chunks_info:"[]",code_count:h,columns:[{index_name:O,key:O,label:"hq_code",source:P,type:f},{domain:w,feKey:Q,index_name:Q,key:Q,label:O,origin_index:"stock code",source:P,type:f,unit:a},{domain:w,feKey:R,index_name:R,key:R,label:"name",origin_index:"stock name",source:P,type:f,unit:a},{feKey:v,index_name:v,key:v,label:"date",origin_index:v,type:"DATE"},{domain:w,feKey:E,index_name:E,key:E,label:a,source:a,timestamp:a,type:S,unit:T},{domain:w,feKey:F,index_name:F,key:F,label:a,source:a,timestamp:a,type:S,unit:T},{domain:w,feKey:G,index_name:G,key:G,label:a,source:a,timestamp:a,type:S,unit:T},{index_name:ah,key:ah,type:f}],condition:"[{\"sonSize\":6,\"opName\":\"and\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"indexProperties\":[\"EQUAL XFOR.O\"],\"indexPropertiesMap\":{\"EQUAL\":\"XFOR.O\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":4,\"opName\":\"or\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@R\\u0026D Expenses\",\"indexProperties\":[\"起始交易日期 20231001\",\"截止交易日期 20240930\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20231001\",\"截止交易日期\":\"20240930\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Net Income\",\"indexProperties\":[\"起始交易日期 20231001\",\"截止交易日期 20240930\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20231001\",\"截止交易日期\":\"20240930\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Total Revenue\",\"indexProperties\":[\"起始交易日期 20231001\",\"截止交易日期 20240930\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20231001\",\"截止交易日期\":\"20240930\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"domain\":\"abs_国际美股领域\",\"relatedSize\":0}]",dataSize:4,datas:[{"Net Income":-19130000,code:u,"R&D Expenses":15272000,Ticker:r,market_code:k,Date:"2023 Q4",Name:n},{"Net Income":-51766000,code:u,"R&D Expenses":19854000,Ticker:r,market_code:k,Date:"2024 Q1",Name:n},{"Net Income":90833000,code:u,"R&D Expenses":20914000,"Total Revenue":563000,Ticker:r,market_code:k,Date:"2024 Q2",Name:n},{"Net Income":-36696000,code:u,"R&D Expenses":19173000,"Total Revenue":560000,Ticker:r,market_code:k,Date:"2024 Q3",Name:n}],meta:{extra:{}},row_count:h,status_code:e,status_msg:"ok"},category:"generic",chart_type:"groupedBar",show_type:af,title_config:{config:{display:b,display2:c,txt_style:e,url:a},data:{h1:ag,h2:a},show_type:N},support_refresh:b,data_config:{query:a,query_type:j,data_ext_params:{}}}],global:{query_type:j},page:{language:a,layout:{layout_data:"[{\"children\":[],\"showType\":\"bar3\",\"uuid\":\"ef6a0c13d86a2302\"}]"},render_for:U},data_config:{query:a,query_type:j,data_ext_params:{}}},tag_info_list:[],is_last:c,uuid:"1376a007-2057-4232-ac3b-e129f8b60111"},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:t,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:B,section:{id:C,info_texts:["Completed"],show_type:D,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:ae,choice:[{display_text:x,query_text:x,trace_info:{item_id:"9c82c3def3129ab23649dd2174260add",item_type:o,item_name:x,rec_info:ai}},{display_text:y,query_text:y,trace_info:{item_id:"46c3c744b95b89240a833d1b68921e58",item_type:o,item_name:y,rec_info:aj}},{display_text:z,query_text:z,trace_info:{item_id:"7035e960cb05f5933c986698076a649c",item_type:o,item_name:z,rec_info:ak}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:N,data:{h1:a,h2:a},config:{display:c,txt_style:e,type:"1",display2:c,url:a}},request_config:[{source_type:al,related_name:am}],puuid:V,tag:a,category:"custom",uuid:an}],global:{urp_static_data:[{name:am,value:{status_code:e,columns:[{type:f,index_name:ao,key:ao},{type:f,index_name:ap,key:ap},{type:f,index_name:aq,key:aq},{type:f,index_name:ar,key:ar},{type:f,index_name:as,key:as}],datas:[{send_text:x,item_type:o,rec_info:ai,display_text:x,rec_reason:a},{send_text:y,item_type:o,rec_info:aj,display_text:y,rec_reason:a},{send_text:z,item_type:o,rec_info:ak,display_text:z,rec_reason:a}],dataSize:al,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:at,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:H,"min-height":"100%",position:au,height:H},isMaterial:c,id:at,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:e,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:W,componentUuid:an,script:[{name:av,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:W,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:W},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:H,position:au,height:H},isMaterial:b,_id:19,id:av,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:U,voice_txt:a,tracking_info:{},uuid:V},order:{is_auto:c,render_for:U,chart_type:"command",puuid:V}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:L,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:I,answer_chain_name:Z},is_deep_research:c,deep_thinking:c,create_time:1746721352021},is_last:b}],questionItem:{data:{qStr:g,encodeFlag:c,imageData:q,docsData:[],quoteData:q},tplType:"question"},events:aw,agentId:a,param:{entity_info:{},add_info:{ori_question:g},event_list:aw,client_ip:a,question:g,user_id:A,user_name:a,trace_id:i,session_id:i,source:p,input_type:aa}}],userId:A,userName:a,startTime:K,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:q,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:e,traceTableData:q,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-x4-pharmaceuticals-revenue-and-expenses-trend-in-q4-2024-71f748\u002F",config:{_app:{basePath:ax,assetsPath:ax,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer",0,"STR","How did X4 Pharmaceuticals' revenue and expenses trend in Q4 2024?",1,"886cdcca-1e3c-4f79-8908-cc9792d8283a","intusstock","186","signal",2001,"X4 Pharmaceuticals","llm_generated","ths_ainvest_lite_web",null,"XFOR.O",999,"rich_text","XFOR","Date","abs_国际美股领域","How did X4 Pharmaceuticals' revenue growth compare to analyst expectations in Q4 2024?","Did X4 Pharmaceuticals report any significant changes in its cost structure in Q4 2024?","How did X4 Pharmaceuticals' cash flow from operations change in Q4 2024 compared to the previous quarter?","dp54012389","progress\u002Fsearching_for",1000,"searching_for","R&D Expenses","Total Revenue","Net Income","auto","agent","XFOR Revenue (Q4 2024), R&D Expenses (Q4 2024), SG&A Expenses (Q4 2024), Net Income (Q4 2024)",1746721331930,"inspect stocks",". \n\n","title1","code","fixed_index","Ticker","Name","DOUBLE","USD","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","X4 Pharmaceuticals experienced a significant decline in net income in Q4 2024, with a net loss of $39.82 million, compared to the previous quarter's net income of $1.43 million. The company's revenue for the quarter was $1.43 million, while the R&D expenses were $21.7 million. \n\n\n|code|Ticker|Name|Date|R&D Expenses|Total Revenue|Net Income|market_code|\n|---|---|---|---|---|---|---|---|\n|XFOR|XFOR.O|X4 Pharmaceuticals|2023 Q4|1.5272E7||-1.913E7|186|\n|XFOR|XFOR.O|X4 Pharmaceuticals|2024 Q1|1.9854E7||-5.1766E7|186|\n|XFOR|XFOR.O|X4 Pharmaceuticals|2024 Q2|2.0914E7|563000|9.0833E7|186|\n|XFOR|XFOR.O|X4 Pharmaceuticals|2024 Q3|1.9173E7|560000|-3.6696E7|186|\n\n","select   stock_code,   total_revenue,   r_d_expenses,   total_expenses,   net_income from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'XFOR.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","X4 Pharmaceuticals experienced a significant decline in net income in Q4 2024, with a net loss of $39.82 million, compared to the previous quarter's net income of $1.43 million. The company's revenue for the quarter was $1.43 million, while the R&D expenses were $21.7 million[^1]","\n``` visual\n{\"uuid\":\"1376a007-2057-4232-ac3b-e129f8b60111\"}\n```","result_page","bar3","XFOR R&D Expenses, Total Revenue...","market_code","2+679_496_21_554+0+0+886cdcca-1e3c-4f79-8908-cc9792d8283a+9c82c3def3129ab23649dd2174260add+llm_generated+aimeTagAnalysis+0+0.01698908396065235+1","2+679_496_21_554+0+0+886cdcca-1e3c-4f79-8908-cc9792d8283a+46c3c744b95b89240a833d1b68921e58+llm_generated+aimeTagAnalysis+0+0.009223482571542263+2","2+679_496_21_554+0+0+886cdcca-1e3c-4f79-8908-cc9792d8283a+7035e960cb05f5933c986698076a649c+llm_generated+aimeTagAnalysis+0+0.0069833071902394295+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>